Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLS | O94925 | 10/20 | 0.50 |
| ▸ | BRAF | P15056 | 1/20 | 0.50 |
| ▸ | P2RY14 | Q15391 | 2/20 | 0.49 |
| ▸ | NTRK1 | P04629 | 3/20 | 0.47 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.47 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.46 |
| ▸ | MMP2 | P08253 | 1/20 | 0.44 |
| ▸ | MMP9 | P14780 | 1/20 | 0.44 |
| ▸ | MMP14 | P50281 | 1/20 | 0.44 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16879170 | 0.86 | MEN1 (0.54) | GLSBRAF | |
| SCHEMBL16887481 | 0.83 | GLS (0.52) | GLSBRAF | |
| SCHEMBL16879501 | 0.82 | BRAF (0.55) | GLSBRAFP2RY14NTRK1NLRP3 | |
| SCHEMBL16879493 | 0.80 | GLS (0.50) | GLSBRAF | |
| SCHEMBL16879549 | 0.80 | BRAF (0.44) | GLSBRAFP2RY14NTRK1CSNK1D | |
| SCHEMBL18525610 | 0.80 | KDM5A (0.52) | — | |
| SCHEMBL16887479 | 0.80 | BRAF (0.43) | GLSBRAFP2RY14NTRK1CSNK1D | |
| SCHEMBL16879527 | 0.79 | GLS (0.52) | GLSP2RY14CSNK1D | |
| SCHEMBL29349722 | 0.78 | GLS (0.60) | GLS | |
| SCHEMBL16879519 | 0.78 | NPC1 (0.52) | GLSBRAFP2RY14NLRP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112920180-A | Glutaminase inhibitors | 理森制药股份公司 | 2021-06-08 | — | — | CN | disclosed |
| CN-105960405-B | Glutaminase inhibitors | 理森制药股份公司 | 2021-02-19 | — | — | CN | disclosed |
| EP-3092235-A2 | NOVEL INHIBITORS OF GLUTAMINASE | Rhizen Pharmaceuticals S.A. (CH) | 2016-11-16 | — | — | EP | disclosed |
| US-20160297761-A1 | NOVEL INHIBITORS OF GLUTAMINASE | RHIZEN PHARMACEUTICALS AG (CH) | 2016-10-13 | — | — | US | disclosed |
| US-20160297761-A1 | NOVEL INHIBITORS OF GLUTAMINASE | RHIZEN PHARMACEUTICALS AG (CH) | 2016-10-13 | — | — | US | disclosed |
| US-20160297761-A1 | NOVEL INHIBITORS OF GLUTAMINASE | RHIZEN PHARMACEUTICALS AG (CH) | 2016-10-13 | — | — | US | disclosed |
| WO-2015101958-A2 | NOVEL INHIBITORS OF GLUTAMINASE | RHIZEN PHARMACEUTICALS SA (CH) | 2015-07-09 | — | — | WO | disclosed |
| WO-2015101958-A2 | NOVEL INHIBITORS OF GLUTAMINASE | RHIZEN PHARMACEUTICALS SA (CH) | 2015-07-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160297761-A1 | NOVEL INHIBITORS OF GLUTAMINASE | GLS, GLS2, GLUL | GLS 1/4885BRAF 2125/4885P2RY14 4686/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.